JP2023502558A - 高効率タンパク質沈殿生成のための組成物及び方法 - Google Patents
高効率タンパク質沈殿生成のための組成物及び方法 Download PDFInfo
- Publication number
- JP2023502558A JP2023502558A JP2022517967A JP2022517967A JP2023502558A JP 2023502558 A JP2023502558 A JP 2023502558A JP 2022517967 A JP2022517967 A JP 2022517967A JP 2022517967 A JP2022517967 A JP 2022517967A JP 2023502558 A JP2023502558 A JP 2023502558A
- Authority
- JP
- Japan
- Prior art keywords
- precipitant
- protein
- precipitate
- supernatant
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title description 4
- 230000006920 protein precipitation Effects 0.000 title description 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 63
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 63
- 239000002244 precipitate Substances 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000006228 supernatant Substances 0.000 claims abstract description 23
- 239000000243 solution Substances 0.000 claims abstract description 12
- 238000001704 evaporation Methods 0.000 claims abstract description 6
- 230000008020 evaporation Effects 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 5
- 238000011026 diafiltration Methods 0.000 claims abstract description 3
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- -1 organic acid salts Chemical class 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000011210 chromatographic step Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 4
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 4
- 239000010836 blood and blood product Substances 0.000 claims description 4
- 229940125691 blood product Drugs 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 229940072221 immunoglobulins Drugs 0.000 claims description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 3
- 102000008946 Fibrinogen Human genes 0.000 claims description 3
- 102100037362 Fibronectin Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 239000003114 blood coagulation factor Substances 0.000 claims description 3
- 235000010633 broth Nutrition 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 229940012952 fibrinogen Drugs 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 3
- 102100036537 von Willebrand factor Human genes 0.000 claims description 3
- 229960001134 von willebrand factor Drugs 0.000 claims description 3
- 102100036774 Afamin Human genes 0.000 claims description 2
- 229940050528 albumin Drugs 0.000 claims description 2
- 108010090535 alpha-albumin Proteins 0.000 claims description 2
- 239000013592 cell lysate Substances 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 abstract description 46
- 239000012460 protein solution Substances 0.000 abstract description 16
- 238000001556 precipitation Methods 0.000 abstract description 9
- 238000005194 fractionation Methods 0.000 abstract description 2
- 235000004252 protein component Nutrition 0.000 abstract description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000012134 supernatant fraction Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000012501 chromatography medium Substances 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000002253 acid Chemical class 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940009550 c1 esterase inhibitor Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000013627 low molecular weight specie Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940021317 other blood product in atc Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010963 scalable process Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/303—Extraction; Separation; Purification by precipitation by salting out
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4055—Concentrating samples by solubility techniques
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N30/12—Preparation by evaporation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Water Supply & Treatment (AREA)
- Ecology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (19)
- 水溶液から所望のタンパク質を単離する方法であって、
前記所望のタンパク質を含む複数の溶媒和したタンパク質を含む水溶液を入手することと、
前記所望のタンパク質を含む沈殿物の形成をもたらさない沈殿剤濃度を提供するように前記水溶液に不揮発性沈殿剤を加えて第一の中間物溶液を形成することと、
前記沈殿剤を保持したまま前記沈殿剤の目標沈殿濃度に到達するまで前記第一の中間物溶液から水を除去して、前記複数のタンパク質の中の第一のタンパク質を含む第一の沈殿物及び前記複数のタンパク質の中の第二のタンパク質を含む第一の上清を生成することと、
前記第一の上清から前記第一の沈殿物を分離することと、
を含む、方法。 - 前記沈殿剤は、有機酸、有機酸塩、無機塩、親水性ポリマからなる群から選択される、請求項1に記載の方法。
- 前記沈殿剤はクエン酸ナトリウムである、請求項1又は2に記載の方法。
- 水は蒸発によって除去される、請求項1から3のうちいずれか一項に記載の方法。
- 蒸発は減圧下にて実施される、請求項4に記載の方法。
- 前記沈殿剤は親水性ポリマであり、水は限外濾過又は透析濾過によって除去される、請求項1から3のうちいずれか一項に記載の方法。
- 前記所望のタンパク質は前記第一のタンパク質である、請求項1から6のうちいずれか一項に記載の方法。
- 前記所望のタンパク質は前記第二のタンパク質である、請求項1から6のうちいずれか一項に記載の方法。
- 第二の沈殿物及び第二の上清を生成させるために前記第一の上清からさらなる水が除去される、請求項1から8のうちいずれか一項に記載の方法。
- 前記水溶液は、血液製剤、細胞培養液、発酵ブロス、及び細胞溶解物からなる群から選択される、請求項1から9のうちいずれか一項に記載の方法。
- 前記血液製剤は、血清、血漿、脱クリオ血漿、及び再溶解クリオプレシピテートからなる群から選択される、請求項10に記載の方法。
- 前記水溶液は別のタンパク質分離プロセスからの中間物である、請求項1から9のうちいずれか一項に記載の方法。
- 前記第一の上清をクロマトグラフィ工程にかけることをさらに含む、請求項1から12のうちいずれか一項に記載の方法。
- 前記第一の沈殿物を再可溶化して第一の再可溶化沈殿物を形成することをさらに含む、請求項1から13のうちいずれか一項に記載の方法。
- 前記第一の再可溶化沈殿物をクロマトグラフィ工程にかけることをさらに含む、請求項14に記載の方法。
- 第二の上清を第一のクロマトグラフィ工程にかけることをさらに含む、請求項9から15のうちいずれか一項に記載の方法。
- 第二の沈殿物を再可溶化して第二の再可溶化沈殿物を形成することをさらに含む、請求項9から16のうちいずれか一項に記載の方法。
- 前記第二の再可溶化沈殿物を第二のクロマトグラフィ工程にかけることを含む、請求項17に記載の方法。
- 前記複数のタンパク質は、フィブリノゲン、フィブロネクチン、凝固因子、フォン・ヴィレブランド因子、免疫グロブリン、アルファ-1アンチトリプシン、及びアルブミンのうち少なくとも一つを含む、請求項1から18のうちいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962903644P | 2019-09-20 | 2019-09-20 | |
US62/903,644 | 2019-09-20 | ||
PCT/US2020/012961 WO2021054998A1 (en) | 2019-09-20 | 2020-01-10 | Compositions and methods for high efficiency protein precipitation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023502558A true JP2023502558A (ja) | 2023-01-25 |
JP7509449B2 JP7509449B2 (ja) | 2024-07-02 |
Family
ID=
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55100321A (en) * | 1979-01-23 | 1980-07-31 | Seiichi Shibata | Production of glycoprotein |
JP2019513119A (ja) * | 2016-02-03 | 2019-05-23 | プラズマ テクノロジーズ エルエルシーPlasma Technologies, Llc | 血液系物質からタンパク質を抽出する方法 |
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55100321A (en) * | 1979-01-23 | 1980-07-31 | Seiichi Shibata | Production of glycoprotein |
JP2019513119A (ja) * | 2016-02-03 | 2019-05-23 | プラズマ テクノロジーズ エルエルシーPlasma Technologies, Llc | 血液系物質からタンパク質を抽出する方法 |
Also Published As
Publication number | Publication date |
---|---|
US10815270B1 (en) | 2020-10-27 |
EP4013768A1 (en) | 2022-06-22 |
CN114585634A (zh) | 2022-06-03 |
EP4013768A4 (en) | 2023-08-23 |
KR20220078618A (ko) | 2022-06-10 |
CA3149770A1 (en) | 2021-03-25 |
AU2020348173A1 (en) | 2022-03-24 |
US11760778B2 (en) | 2023-09-19 |
US20210087228A1 (en) | 2021-03-25 |
WO2021054998A1 (en) | 2021-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210261608A1 (en) | Methods for Extracting Proteins from a Blood-Based Material | |
US11739117B2 (en) | Therapeutic protein compositions and methods | |
US11760778B2 (en) | Compositions and methods for high efficiency protein precipitation | |
Salvi et al. | Purification and proteomic analysis of chloroplasts and their sub-organellar compartments | |
Ikeuchi et al. | Behavior of the 36,000-dalton protein in the internal membranes of squash etioplasts during greening | |
JP7509449B2 (ja) | 高効率タンパク質沈殿生成のための組成物及び方法 | |
AU2020348173B2 (en) | Compositions and methods for high efficiency protein precipitation | |
WO2023154822A8 (en) | Methods of purifying a product | |
US6103502A (en) | Ultrafiltration process for desalination and concentration of a peptide in a cell-free fermentation medium | |
US20210087224A1 (en) | Compositions and methods for generating modified cryo poor plasma | |
US20220402969A1 (en) | Methods for Extracting Proteins from a Blood-Based Material | |
JP5931363B2 (ja) | タンパク質の精製方法 | |
CA2743499C (en) | Phosphopeptide enrichment of compositions by fractionation on ceramic hydroxyapatite | |
JPH07203863A (ja) | 牛乳ホエ−由来β−ラクトグロブリン、α−ラクトアルブミン及びラクトフエリンの製造法 | |
US20240166685A1 (en) | Systems and methods for process scale isolation of a protein | |
JP2017025025A (ja) | タンパク質の精製方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220921 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230831 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230905 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240304 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240528 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240613 |